SPONSOR

AstraZeneca

Total Trials

Recruiting

Phases

Phase 3, Phase 1, Phase 4, Phase 2, Phase 1, Phase 2

Conditions studied: Neurofibromatosis 1 Neurofibroma, Plexiform Asthma Adenocarcinoma (NOS)Anal Cancer Bladder Cancer Cervical Cancer Endometrial Cancer Esophageal Cancer Gall Bladder Cancer

AstraZeneca is a British-Swedish multinational biopharmaceutical company with one of the industry's most active clinical pipelines in oncology, cardiovascular-renal-metabolic disease, respiratory and immunology, and rare diseases. Founded in 1999 through the merger of Astra AB and Zeneca Group, AstraZeneca today invests approximately $9–10 billion annually in R&D. Their trial portfolio is notable for several landmark programs including the DAPA-HF and DAPA-CKD trials (dapagliflozin), the ADAURA and LAURA trials (osimertinib for lung cancer), and the AstraZeneca-Oxford COVID-19 vaccine development.

AstraZeneca's oncology unit — operating as AstraZeneca Oncology — maintains deep expertise in targeted therapy for EGFR-mutated non-small cell lung cancer, HER2-targeted therapies (trastuzumab deruxtecan, developed with Daiichi Sankyo), PARP inhibitors for ovarian and breast cancer (olaparib), and immuno-oncology through the PD-L1 inhibitor durvalumab. The cardiovascular and metabolic portfolio includes one of the most extensive SGLT2 inhibitor trial programs ever conducted, spanning heart failure, chronic kidney disease, and type 2 diabetes across thousands of participants in dozens of countries.

AstraZeneca's clinical trials are conducted at leading academic and community research centers worldwide. The company has made public commitments to diversity in clinical research and has implemented specific protocols to increase enrollment from historically underrepresented groups. AstraZeneca participates in pre-competitive partnerships through organizations such as the Innovative Medicines Initiative (IMI) and TransCelerate BioPharma.

Frequently Asked Questions — AstraZeneca

What is AstraZeneca best known for in clinical research?

AstraZeneca is best known clinically for three major areas: (1) lung cancer — their EGFR inhibitor osimertinib (Tagrisso) demonstrated unprecedented survival improvements in adjuvant NSCLC and is the subject of ongoing trials in earlier disease stages and combination settings; (2) heart failure and kidney disease — dapagliflozin (Farxiga) has been shown in Phase 3 trials to significantly reduce hospitalization and mortality across both heart failure subtypes and in CKD independent of diabetes; and (3) PD-L1 inhibition — durvalumab (Imfinzi) has received approvals in multiple cancer indications and is under investigation in dozens of additional combinations.

Does AstraZeneca run trials outside of cancer?

Yes. While oncology represents the largest share of AstraZeneca's current trial portfolio, the company has equally robust programs in cardiovascular, renal, and metabolic disease (CVRM), respiratory and immunology, and rare diseases. Their CVRM trials include investigations of SGLT2 inhibitors, GLP-1/GIP agonists (in collaboration with partners), and novel mechanisms in heart failure. The respiratory portfolio covers severe asthma (benralizumab, tezepelumab), COPD, and interstitial lung disease. Rare disease trials focus on conditions with high unmet medical need including complement-mediated diseases and severe respiratory disorders.

How does AstraZeneca approach diversity and inclusion in clinical trials?

AstraZeneca has a published global diversity and inclusion framework for clinical trials that sets targets for enrollment of women, patients from racial and ethnic minority groups, and older adults across all Phase 2 and Phase 3 studies. The company works with community organizations and patient advocacy groups to identify and address barriers to participation — including transportation, language, and lack of awareness — particularly for oncology and rare disease trials where underrepresentation has historically been greatest. These commitments are reported annually in AstraZeneca's Global Sustainability Report.

AstraZeneca

Frequently Asked Questions — AstraZeneca

Clinical Trials by AstraZeneca

Real-World Treatment Study of Koselugo (Selumetinib)

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

DESTINY-PANTUMOUR04

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

AZD5305 hADME in Patients With Advanced Solid Malignancies

A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population

Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.

NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

The Anifrolumab PRIM Program

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil

Study That Will Evaluate the Brazilian Population With COPD.

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants

NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

Ravulizumab Outcomes in Polish Patients With aHUS

iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases

MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.